PTC Therapeutics, Inc.
General ticker "PTCT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.6B
PTC Therapeutics, Inc. follows the US Stock Market performance with the rate: 58.4%.
Estimated limits based on current volatility of 2.4%: low 44.53$, high 46.70$
Factors to consider:
- Current price 21.0% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [15.90$, 37.64$]
- 2024-12-30 to 2025-12-30 estimated range: [14.99$, 34.41$]
Financial Metrics affecting the PTCT estimates:
- Negative: Non-GAAP EPS, $ of -6.54 <= 0.10
- Negative: Operating profit margin, % of -29.20 <= 1.03
- Negative: Operating cash flow per share per price, % of -7.55 <= 2.35
- Negative: negative Net income
- Positive: -3.48 < Investing cash flow per share, $ of -2.36
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Inventory ratio change, % of -0.03 <= 0
Short-term PTCT quotes
Long-term PTCT plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $539.09MM | $724.70MM | $1,065.52MM |
| Operating Expenses | $913.54MM | $1,172.11MM | $1,505.02MM |
| Operating Income | $-374.44MM | $-447.41MM | $-439.50MM |
| Non-Operating Income | $-143.90MM | $-140.08MM | $-256.61MM |
| Interest Expense | $86.02MM | $90.87MM | $129.18MM |
| R&D Expense | $540.68MM | $651.50MM | $666.56MM |
| Income(Loss) | $-518.34MM | $-587.49MM | $-696.11MM |
| Taxes | $5.56MM | $-28.47MM | $-69.51MM |
| Profit(Loss) | $-523.90MM | $-559.02MM | $-626.60MM |
| Stockholders Equity | $1.44MM | $-347.09MM | $-818.55MM |
| Inventory | $15.86MM | $21.81MM | $30.58MM |
| Assets | $1,938.06MM | $1,705.62MM | $1,895.70MM |
| Operating Cash Flow | $-251.33MM | $-356.65MM | $-158.42MM |
| Capital expenditure | $85.33MM | $152.46MM | $120.62MM |
| Investing Cash Flow | $219.18MM | $290.18MM | $-176.74MM |
| Financing Cash Flow | $20.88MM | $167.95MM | $646.40MM |
| Earnings Per Share* | $-7.43 | $-7.79 | $-8.37 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.